On October 1, 2021, the U.S. Food and Drug Administration (FDA) approved brexucabtagene autoleucel for adult patients with relapsed or refractory (R/R) B-cell precursor acute lymphoblastic leukemia (ALL).
Read the FDA announcement.
Read Kite Pharma's announcement.
Posted 10/4/2021
